CorAssist Cardiovascular - Innovative Solutions for heart failure with preserved ejection fraction (HFpEF)
CorAssist is committed to developing innovative
therapeutic devices for treating
heart failure with preserved
ejection fraction (HFpEF)
CorAssist Cardiovascular - Innovative Solutions for Heart Failure with Preserved Ejection Fraction (HFpEF)

About Heart Failure with Preserved Ejection Fraction (HFpEF)

HFpEF is characterized by the inability of the LV to relax properly and fill with blood. This is caused by stiffening and impaired relaxation with normal systolic function, either due to hypertrophy or to processes such as fibrosis and infiltrative diseases. These changes cause high LV filling pressures, leading to pulmonary congestion and atrial fibrillation due to distention of the atrium.

The risk factors for HFpEF include advancing age, obesity, hypertension and diabetes. Additional causes are amyloidosis, ventricular hypertrophy and diffuse myocardial fibrosis (Braunwald E, Zipes DP, Libby P (editors). Heart disease: A textbook of cardiovascular medicine. W.B. Saunders Company Publishers. 6th edition, 2001:534-561).

There are currently no approved devices to treat this condition.

The prevalence of preserved ejection fraction among Patients with a discharge diagnosis of heart failure increased over time The average prevalence increased to about 50 percent. (Oktay A, Shah SJ. Curr Cardiol Rev, 2013)